Rob Bookstein

Rob Bookstein is a highly experienced molecular pathologist currently serving as Principal Molecular Pathologist at Adaptive Biotechnologies Corp. since September 2018, with a focus on the clonoSeq assay for lymphoid malignancies. Previous roles include Assistant Clinical Molecular Genetic Laboratory Director at Illumina Ventures, Consultant and Pathologist at Cedars-Sinai Medical Center, and Director of Corporate and Venture Development at Illumina, where Rob engaged in IVD partnerships and diagnostics investments. Earlier in the career, Rob held leadership positions at Biogen Idec, Schering-Plough BioPharma, and Canji, Inc., contributing to oncology investments and molecular biology research. Educational qualifications include a BA in Biology from UC San Diego and an MD from Yale University School of Medicine.